Acousia Therapeutics GmbH
Acousia Therapeutics is a pioneering biotech company dedicated to developing novel medicines to treat and prevent sensorineural hearing loss (SNHL). Founded in 2012 and based in Tübingen, Germany, the company focuses on small molecule drug candidates that enhance and preserve natural hearing, addressing a significant unmet medical need. With a strong management team, collaborations with leading research groups, and a robust pipeline of clinical and preclinical programs, Acousia aims to make hearing loss a treatable condition and improve quality of life for millions affected worldwide.
Industries
Nr. of Employees
small (1-50)
Acousia Therapeutics GmbH
Products
Local sustained‑release Kv7.4 activator formulation for otoprotection (lead clinical candidate)
A first-in-class small-molecule Kv7.4 channel activator formulated as a slow-release transtympanic gel to provide prolonged local cochlear exposure for acute otoprotection and to reduce hair cell loss.
Oral systemic Kv7.4 activator candidate for chronic hearing loss
An oral small-molecule Kv7.4 activator developed for systemic administration to acutely enhance hearing function and to preserve hearing capacity in chronic progressive conditions such as age-related hearing loss.
Local sustained‑release Kv7.4 activator formulation for otoprotection (lead clinical candidate)
A first-in-class small-molecule Kv7.4 channel activator formulated as a slow-release transtympanic gel to provide prolonged local cochlear exposure for acute otoprotection and to reduce hair cell loss.
Oral systemic Kv7.4 activator candidate for chronic hearing loss
An oral small-molecule Kv7.4 activator developed for systemic administration to acutely enhance hearing function and to preserve hearing capacity in chronic progressive conditions such as age-related hearing loss.
Services
Translational research collaborations and preclinical development
Collaborative research partnerships providing target validation, assay development, in‑vivo proof‑of‑concept studies, and preclinical pharmacology to advance small-molecule otoprotectants toward clinical evaluation.
Clinical development and trial execution for otoprotectant candidates
Design and management of early and mid-stage clinical studies in otoprotection, including safety/tolerability assessments and specialized audiological outcome measurements in multi-site settings.
Translational research collaborations and preclinical development
Collaborative research partnerships providing target validation, assay development, in‑vivo proof‑of‑concept studies, and preclinical pharmacology to advance small-molecule otoprotectants toward clinical evaluation.
Clinical development and trial execution for otoprotectant candidates
Design and management of early and mid-stage clinical studies in otoprotection, including safety/tolerability assessments and specialized audiological outcome measurements in multi-site settings.
Expertise Areas
- Small-molecule drug discovery for sensorineural hearing loss
- Kv7.4 (KCNQ4) channel-targeted therapeutics
- Preclinical ototoxicity and age-related hearing loss models
- Formulation development for local and systemic inner-ear delivery
Key Technologies
- Kv7.4 (KCNQ4) channel modulation
- Small-molecule therapeutics
- Transtympanic sustained-release gel delivery
- Oral systemic small-molecule delivery